Newsletters

NEUROFIT is a pre-clinical CRO offering set of in vitro and in vivo screening assays for psychiatry, neurology, multiple sclerosis and pain.
NEUROFIT's repertoire of screening tests is extensive and a full catalogue can be found on THERAPEUTIC AREA or TESTS with reference data.


About us Validation data Publications

Legende :
Animal models
Cellular models
Animal and Cellular models

Please find our recent newsletters:


117 - From neuroplasticity to behavior: the therapeutic promise of 2,5-Dimethoxy-4-iodoamphetamine (DOI) as a 5-HT2A agonist
116 - Methotrexate: Versatility and Preclinical Insights
113 - Combined Effects of Fluoxetine and Memantine on OCD-Related Compulsions
112 - Metformin beyond diabetes: unveiling neuroprotective potentials
111 - Cariprazine: unveiling its distinctive profile and cognitive benefit in schizophrenia
110 - Breaking Boundaries in Panic Disorder: Unveiling Clonidine's Unique Role and Translational Triumphs in Preclinical Models
109 - Deciphering the Neuroprotective Benefit of NSAIDs - Correlation with Preclinical Evidence
108 - In vitro assay of neurotrophic activity
107 - Insights into L-BMAA-Induced Neuronal Injury symptoms
106 - Spermidine: a multifaceted cellular player
105 - Rapid psychoactive action of Rapastinel free of psychomimetic symptoms
104 - Pridopidine rescues Schizophrenia cognitive impairment
103 - Zuranolone, a neuroactive steroid with a fast-developing CNS effect
102 - Semaglutide reduces weight gain and improves memory deficit in the rat
101 - Psychoactive therapeutics promote neurite outgrowth
100 - Cinnamaldehyde ameliorates brain inflammation-related cognitive deficit
99 - Modafinil: treatment of Schizophrenia / depression co-morbidity
98 - Metformin, potential remyelination agent via proliferation of OPC
97 - DHA improves inflammation-related cognitive deficit
96 - Antioxidant N-Acetylcysteine improves cognitive symptom of Schizophrenia
95 - Subchronic GLP-1 mimetic treatment improves amyloid-beta -induced memory deficit
94 - D-cycloserine improves memory and anxiety like-behavior in rodents
93 - Phosphodiesterase inhibition improves cognitive deficit
92 - Resveratrol reverses inflammation-induced cognitive decline
91 - Ginkgo biloba improves cognitive deficit and anxiety like-behavior in mice
90 - Neflamapimod improves inflammation-driven cognitive deficit
89 - EMG to investigate the in-vivo myorelaxant effect of anti-wrinkle compound
88 - Predictive CNS tests for nutraceuticals
87 - Drug combination therapy in psychiatric animal disease models
86 - Model of Relapsing Remitting MS that responds to Teriflunomide
85 - Translational model of Autism
83 - Mouse model of schizophrenia: reversal effect of Vortioxetine
82 - Clinically Relevant In-vivo assay for anti-spasticity treatment
81 - Neurodegenerative diseases: chronic glutamate excitoxicity
80 - Passive Avoidance test
79 - Yohimbine-induced panic-like behavior in the rat
78 - Ketamine-sensitive assay for neuropsychiatric disorders
77 - Parkinson's Disease: catalepsy model
76 - Elevated Plus Maze (EPM)
75 - Riluzole, a medication for ALS
74 - Pharmacological relevance of the Open-Field Test
73 - Modafinil: a "smart drug" that promotes Cognitive Function
71 - Sciatic nerve crush, animal model of peripheral nerve injury
70 - RESVERATROL: A potent antioxidant and neuroprotector
69 - Chemotherapy-induced peripheral neuropathy
68 - Intranasal drug administration in a classical translational model of cognitive deficits
67 - Preclinical model of Allergic contact dermatitis: Calcipotriol (topic) and Apremilast (per os)
66 - Evaluation of anti-depressant and/or anxiolytic drugs: Venlafaxine validation
65 - Alzheimer preclinical model for the evaluation of cognitive-enhancing drugs: Memantine validation
63 - Translational model of Schizophrenia - Phencyclidine (PCP)
61 - Neurocellular model of Parkinson's disease - MPP+ neurotoxicity
60 - Translational model of DELAYED-TYPE HYPERSENSITIVITY
59 - Translational model of Multiple Sclerosis - Remittance and disease relapse
58 - Evaluation of nerve / axonal regeneration
57 - New functional assay for Amyloid β lowering drugs
56 - In-vivo model of cognitive disorders in schizophrenia
55 - Animal model of inflammation-induced cognitive decline
54 - Human iPSC-derived Neurons
53 - A clinically translatable rat model of Panic Anxiety
52 - In-vivo screening of antidepressant: forced swimming test
51 - Glutamate excitotoxicity
50 - Diabetic neuropathy
49 - Neuritogenesis, a neuroadaptive mechanism of antidepressant drugs action
48 - A functional model of motor unit Rat nerve - Human muscle coculture
47 - Preclinical models for the evaluation of cognitive-enhancing drugs
46 - Reversal of MK-801-induced cognitive dysfunction by nicotine and donepezil in the T-maze assay
45 - Automated formalin test - Animal model of Neuropathic pain
44 - Rodent model of Parkinson's disease
43 - Animal model responding to ADHD therapy
42 - Cellular model of brain inflammation and neuronal death
41 - Neuronal Schwann cell assays
40 - Parkinson disease model: 6-OHDA-mediated neuronal death
39 - Neurite outgrowth evaluation on primary neuronal culture
38 - Animal model of Relapsing-Remitting Multiple Sclerosis
37 - Oxazolone-induced contact dermatitis
36 - Animal model of nerve / axonal regeneration
35 - Animal Model of Allergic contact dermatitis
34 - A functional model of motor unit Rat nerve - Human muscle coculture
33 - Light-Dark test in the mouse: Reliable anxiety screening test
32 - Non-transgenic animal model of Alzheimer's disease that responds to donepezil treatment
31 - Animal model for Rheumatoid Arthritis: Pristane induced arthritis in rat
30 - Animal model of contact dermatitis
29 - Formalin test : Assay for anti-nociceptive drugs screening
28 - Sciatic Nerve Crush in mice
27 - Preclinical use of electrodiagnostic testing
26 - Schizophrenia
25 - DONEPEZIL: Neurotrophic and cognitive-enhancing drug
24 - Carrageenan: Air-Pouch model in the mouse
23 - Degeneration of intra-epidermal nerve fibers (IENF)
22 - Robust disease model for Relapsing-Remitting Multiple Sclerosis
21 - Rapid, sensitive, cost effective assay for the screening of cognitive enhancer compounds
20 - New in-vivo model of Panic Anxiety available at Neurofit
19 - Animal model of Relapsing-Remitting Multiple Sclerosis
18 - Collection of brain microstructures
17 - Rodent Elevated Plus Maze (EPM)
16 - Parkinson's Disease model
15 - Model of MPP+ - induced neurotoxicity in rat dopaminergic neurons
14 - Wire-hanging test model
13 - Model of β-Amyloid-induced neurotoxicity in rat Hippocampal neurons
12 - Reversal of MK-801-induced cognitive dysfunction by nicotine and donepezil in the T-maze assay
11 - Novel object recognition test in the rat
10 - Collagen-induced arthritis ( CIA ) in the rat
09 - T-maze Continuous Alternation Task (T-CAT) in the mouse
08 - In vitro assay of neurotrophic activity
06 - Conditioned Place Preference Test
05 - Animal models of anxiety
03 - A functional model of motor unit : Rat nerve - Human muscle coculture
02 - Amyotropic Lateral Sclerosis (ALS or Lou Gehrig's disease)
01 - Multiple sclerosis - Drug screening


If you need further information, please do not hesitate to contact us.
On a regular basis we distribute newsletters with scientific information on our research services.
If you wish to receive these, please sign up on our mailing list: